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28 Consecutive COPD patients performed four 6-minutewalking tests (6-MWTs) in 2 different days
before and 2, 4 and 6 h after the inhalation of formoterol 12 mg or tiotropium 18 mg, respectively.
Physical activity during each 6-MWTwas assessed by the SenseWear Armband. At each time also
spirometry was performed. Both formoterol and tiotropium induced a significantly sustained
bronchodilation and influenced hyperinflation. Formoterol significantly increased distance
walked in 6 min at 2 h and at 4 h, whereas tiotropium significantly increased it at all time points.
There was a trend to an increase in calories and metabolic equivalents of task (METs) after for-
moterol and a decrease after tiotropium, but changes were not statistically significant. Total
energy expenditure for each 6-MWTwas not changed by formoterol, but decreased in significant
manner 6 h after the inhalation of tiotropium. Active energy expenditure at physical activity level
of more than 3 METs decreased significantly after tiotropium at each 6-MWT, but not after formo-
terol. We did not find any significant correlation between the changes in lung function and those
of parameters recordedwith SenseWear Armband. Our study seems to indicate that tiotropium,
but not formoterol, is able to reduce energy expenditure in COPD patients, although both drugs
elicit significant bronchodilation and are able to increase the distance walked in 6 min.
ª 2010 Elsevier Ltd. All rights reserved.to di Medicina Interna, Via
: þ39 062090 3615.
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Energy expenditure (EE) may be elevated in COPD patients
due to increased basal metabolic rate, increased activity
expenditure, or an increase in nutrient-induced thermo-
genesis.1 Increased oxygen cost of breathing probably
contributes to the increased total daily EE due to increased.
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effects of bronchodilating agents4 and systemic inflamma-
tion5 are other suggested contributors to the elevated EE.
Long-acting bronchodilators are now central to the
symptomatic management of COPD,6 but there is no docu-
mentation on their impact on EE, although there is
evidence that these agents can reduce lung hyperinflation
during exercise.7,8
The apparent discrepancy between the favourable
action of bronchodilators on exercise-induced hyperinfla-
tion and their potential thermogenic effects, has led us to
undertake the present study for assessing the influence of
tiotropium and formoterol, two long-acting bronchodilators
with different pharmacological mechanisms of action,
being the first an anticholinergic agent and the second
a b-agonists, on EE during physical activity in patients with
COPD.
Patients and methods
We enrolled 28 consecutive COPD outpatients as defined by
the American Thoracic Society (ATS)/European Respiratory
Society (ERS) position paper.6 All had a baseline FEV1< 60%
predicted. Exclusion criteria included: unstable respiratory
status within the previous four weeks, a known history of
asthma or chronic respiratory disease other than COPD, any
clinically significant concurrent disease, and a change in
medication for COPD within the four weeks prior to the
screening visit.
The protocol was approved by the ethics committee, and
written informed consent was obtained from all subjects.
All patients were ex-smokers, older than 60 years, and
all had experience of walking tests. They performed four
6-minute walking tests (6-MWTs) in each of 2 separate test
days, before and 2, 4 and 6 h after the inhalation of for-
moterol 12 mg or tiotropium 18 mg, respectively. The
washout period between the test days was at least 96 h to
avoid any carryover effect of tiotropium9 or formoterol.
During this period, the patients could use salbutamol 200 mg
as needed as “rescue” drug. The sequence of treatments
was randomized.
The 6-MWTs were conducted according to current
guidelines on a 30-m corridor.10
EE was assessed during all walking tests by the Sense-
Wear Armband (BodyMedia Inc., Pittsburgh, PA, USA),
a physiologic activity monitor worn on the upper right arm
over the triceps muscle, which contains a biaxial acceler-
ometer (longitudinal and transverse). It also uses sensors
that continuously gather data (i.e. movement, heat flux,Table 1 Changes in lung function before each 6-MWT. Values a
Formoterol
FEV1 FVC TLC RV
Basal 1.42 0.10 2.73 0.13 7.25 0.23 4.30 0.18
2 h 1.62 0.10*** 3.10 0.14*** 7.16 0.23 3.82 0.15**
4 h 1.60 0.09*** 3.02 0.13*** 7.16 0.22 3.90 0.17**
6 h 1.55 0.09*** 3.00 0.13*** 7.11 0.23 3.84 0.15**
*p< 0.05; **p< 0.01; ***p< 0.001.skin temperature, galvanic skin response) estimating the
wearer’s caloric expenditure, duration of physical activity
and number of steps taken. Early research, which tested
COPD patients with this device and with indirect calorim-
etry during two 6-MWTs as well as during two incremental
shuttle walking tests, showed that it tracked very well to
indirect calorimetry with very high session correlations
(0.93).11 During each test day, patients wore the Sense-
Wear Armband for 7 h. The first hour was not used for
analysis because the sensors require 30e40 min to reach
thermal equilibrium.
At each time, soon before each 6-MWT, also spirometry
was performed according to ATS/ERS guidelines.12
The results of the study are expressed as mean and 95% CI
unless otherwise stated. The extent to which the two bron-
chodilators were able to induce changes in the measured
variables was examined using a paired t test. The end-
exercise values for the measured variables obtained during
6-MWT were compared using paired t tests and Bland and
Altman analyses. A p< 0.05 level of significance was used for
all analyses. Since the variables from the physical activity
assessment were non-normally distributed, correlations
between pulmonary function and physical activity were
performed using the Spearman correlation coefficient.
Results
All 28 subjects completed the study and there were no
missing data.
Both formoterol and tiotropium induced a significant
(p< 0.05) bronchodilation and reduced pulmonary hyper-
inflation (Table 1).
Formoterol significantly (p< 0.05) increased distance
walked in 6 min at 2 h and at 4 h, whereas tiotropium
significantly (p< 0.05) increased it at all time points
(Fig. 1).
There was a trend toward an increase in calories after
formoterol (maximum increase: þ0.89 kcal, 95% CI:
2.70e0.91 at 2 h) and decrease after tiotropium (maximum
decrease: 1.61 kcal, 95% CI: 0.60e3.82), but changes
were always statistically non-significant (p> 0.05). Also
metabolic equivalents of task (METs) increased after for-
moterol (maximum increase: þ0.18, 95% CI: 0.44e0.08, at
2 h) and decreased after tiotropium (maximum decrease:
0.22, 95% CI: 0.09e0.52, at 4 h) in a non-significant
manner (p> 0.05) (Fig. 1).
Total energy expenditure (TEE) for each 6-MWT was not
changed by formoterol, but decreased in significant
manner (pZ 0.02) 6 h after the inhalation of tiotropium.re mean S.E.
Tiotropium
FEV1 FVC TLC RV
1.40 0.08 2.72 0.11 7.30 0.24 4.37 0.19
* 1.52 0.09** 2.88 0.14* 7.14 0.22* 3.98 0.16***
1.53 0.09** 2.95 0.14* 7.09 0.23** 3.95 0.14***
* 1.49 0.09** 2.95 0.13** 7.16 0.25* 4.01 0.15***
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Figure 1 Impact of formoterol and tiotropium on distance walked in 6 min, calories and METs. Values are mean S.E. *p< 0.05 vs
baseline.
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Figure 2 Impact of formoterol and tiotropium on total
energy expenditure (TEE) and active energy expenditure (AEE).
Values are mean S.E. *p< 0.05 vs baseline.
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of more than 3 METs during each 6-MWT decreased signif-
icantly after tiotropium (2.32 kcal/6 min, 95% CI: 0.25
to 4.39, pZ 0.03 at 2 h; 3.04 kcal/6 min, 95% CI: 0.49 to
5.58, pZ 0.0211 at 4 h; 2.68 kcal/6 min, 95% CI: 0.30 to
5.05, pZ 0.03 at 6 h) but not after formoterol (Fig. 2). It
must be highlighted that formoterol induced a slight
increase in TEE and AEE, at least in the early hours after its
administration, but the recorded increases were never
statistically significant (p> 0.05).
We did not find any significant correlation between the
changes in lung function and those of parameters recorded
with SenseWear Armband.
Discussion
Our study seems to indicate that tiotropium but not for-
moterol is able to reduce EE in COPD patients although both
drugs elicit significant bronchodilation and are able to
increase the distance walked in 6 min. This finding fits
rather well with the results of a previous study who docu-
mented that salbutamol, a b-agonist, but not ipratropium
bromide, an anticholinergic agent, induced a sustained
increase in the EE of patients with COPD despite a reduc-
tion in airway obstruction obtained with both drugs.13
The effect of tiotropium on EE appeared to be inde-
pendent of its impact on lung function. This is an unex-
pected finding. There is documentation of a reduction in EE
following lung volume reduction surgery in subjects with
COPD and it was suggested that it was related to an
improvement in work of breathing.14 In our patients, both
formoterol and tiotropium were able to induce a pharma-
cologic lung volume reduction but formoterol did not
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reduction in pulmonary hyperinflation is not enough to also
induce a reduction in EE.
Theoretically, bronchodilators could have two opposite
effects on EE in patients with airway obstruction e firstly an
increase in EE due to a direct thermogenic effect and
secondly a decrease in EE due to diminished work of
breathing because of bronchodilation.13
The peripheral sympathetic nervous system is a key factor
in the regulation of energy balance in humans. Appreciable
increases in EE were observed during administration of
isoproterenol with co-infusion of the selective b1-adreno-
ceptor (AR) antagonist atenolol,15 and also during selective
b2-AR stimulation with salbutamol.
16 This finding clearly
indicates that the b2-AR subtype contributes significantly to
b-AR-mediated thermogenesis. Consequently also for-
moterol has the potential for increasing EE. In effect, in our
patients it induced by trend a slight increase in TEE and AEE,
at least in the early hours after its administration, with
a modest reduction at the sixth hour, but changes were
without statistic significance, likely because of the lack of
statistical power (e.g., from small sample size). On the
contrary, tiotropium, being an anticholinergic drug, is a non-
thermogenic bronchodilator13 and, as expected, it did not
elicit an increase in EE after its administration but only its
significantprogressive reduction.The trendthatwedetected
seems to be comparable to what has been observed in horses
with the similar disease, recurrent airway obstruction. Sal-
butamol resulted in a <10% decrease in EE,17 whereas ipra-
tropium bromide resulted in a far more striking reduction in
EE, with all horses experiencing >10% change in EE.18
It is difficult to determine how important the different
impact of formoterol and tiotropium on EE may be in the
clinical setting. We must admit that there are several study
limitations that need to be addressed. We recognize that the
relatively small sample size of patients enrolled in this study
could be regarded as a limitation, but it must be considered
that this study was conducted in a single centre as a pilot
investigative trial. One could argue that a 6-MWT, with
uncontrolled speed and distance, is inappropriate to test the
hypothesis implied. It is possible that the 6-MWT is unlikely to
replace an objective measurement of physical activity when
thewhole range of COPD severity is investigated.19 However,
a preliminary investigation, which evaluated reliability,
validity, and stability of an accelerometer in the measure-
ment of activity during 6-MWT, reported a highly linear
association between accelerometer activity and distance
walked during three walk tests, suggesting that the accel-
erometer is a valid measure of physical movement during
walking in functionally-limited patients.20
SenseWear Armband provides a reasonable approach to
estimate EE in healthy subjects and in patients with COPD
over a longer period of time in a setting, where no other
technology is available (i.e. at home). Whether it is able to
capture such very small differences in EE of about 1e2 kcal
in 6 min is lacking validation so far and our study is the first
attempt to examine this possibility.
Although all patients enrolled in our study had previous
experience of walking tests, our findings do not allow
excluding that the supposed impact of a learning experi-
ence when repetitive tests are performed has influenced
the results that we have obtained.We must also mention that our data have been gener-
ated after the acute administration of the two bronchodi-
lators, whereas it is possible that their chronic use may
have a different impact, at least with respect to for-
moterol. It is well known that the continuous long-term
exposure of b-ARs to agonists results in the downregulation
of mRNA and receptor protein with the rapid onset of
tolerance to their effects.21 Therefore, the thermogenic
effect of formoterol would be expected to be transient in
nature and it likely that the regular use of this drug does
not affect the EE in COPD patients.
In any case, it must be mentioned again that in our
patients both formoterol and tiotropium reduced pulmo-
nary hyperinflation although all patients underwent several
6-MWTs in the same day and it is well known that in patients
with COPD, dynamic hyperinflation can occur during activ-
ities such as walking,22 but only tiotropium reduced EE. It is
clear that large and prolonged studies focused on this
outcome are now mandatory if we want to understand
whether there is a real advantage in using anticholinergic
agents instead of b-agonists in these patients.Conflict of interest
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